Overview

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Status:
Terminated

Trial end date:
2016-05-10

Target enrollment:

Participant gender:

Summary

This is a phase I study to determine the safety and feasibility of the combination of enzalutamide and niraparib in subjects with metastatic castration-resistant prostate cancer (CRPC).

Phase:

Phase 1

Details

Lead Sponsor:

Paul Mathew, MD

Collaborators:

Hoosier Cancer Research Network
Tesaro, Inc.

Treatments:

Niraparib